Skip to main content
TipRanks
Go Ultimate75% OFF

Johnson & Johnson (JNJ) Revenue by Segment

28,732 Followers

Revenue by Segment

In Q3 2026, Johnson & Johnson reported revenue by segment of $16.76B (Pharmaceutical) and $8.64B (Medtech).

Breaks revenue down by business line—primarily pharmaceuticals and medical devices for J&J—revealing which segments deliver the most sales and profits. Makes it easier to judge dependence on blockbuster drugs or device portfolios, see where margins are strongest, and assess how R&D or regulatory risks in a single segment could affect overall performance.

$0.00$5.00B$10.00B$15.00B$20.00B$25.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Consumer Health falls to zero from mid‑2023 onward because J&J completed the spin‑off/divestiture, leaving Pharmaceuticals and MedTech as the core drivers. Pharmaceuticals show clear acceleration fueled by multiple high‑growth launches that largely offset STELARA’s steep decline, underpinning management’s raised FY26 sales/EPS guidance. MedTech growth is steadier but faces selective cardiovascular/Abiomed and China inventory headwinds—key risks to near‑term upside; watch STELARA’s trajectory, procedural recovery, and upcoming pipeline/M&A catalysts for sustainability.

JNJ Revenue by Segment

PeriodPharmaceuticalMedtechConsumer Health
Q3 2026Sep 30, 2026$16.76B$8.64B$0.00
Q2 2026Jun 30, 2026$16.38B$8.93B$0.00
Q1 2026Mar 31, 2026$15.43B$8.64B$0.00
Q4 2025Dec 31, 2025$15.76B$8.80B$0.00
Q3 2025Sep 30, 2025$15.56B$8.43B$0.00
Q2 2025Jun 30, 2025$15.20B$8.54B$0.00
Q1 2025Mar 31, 2025$13.87B$8.02B$0.00
Q4 2024Dec 31, 2024$14.33B$8.19B$0.00
Q3 2024Sep 30, 2024$14.58B$7.89B$0.00
Q2 2024Jun 30, 2024$14.49B$7.96B$0.00
Q1 2024Mar 31, 2024$13.56B$7.82B$0.00
Q4 2023Dec 31, 2023$13.72B$7.67B$0.00
Q3 2023Sep 30, 2023$13.89B$7.46B$0.00
Q2 2023Jun 30, 2023$13.73B$7.79B$4.01B
Q1 2023Mar 31, 2023$13.41B$7.48B$3.85B
Q4 2022Dec 31, 2022$13.16B$6.78B$3.77B
Q3 2022Sep 30, 2022$13.21B$6.78B$3.79B
Q2 2022Jun 30, 2022$13.32B$6.90B$3.81B
Q1 2022Mar 31, 2022$12.87B$6.97B$3.59B
Q4 2021Dec 31, 2021$14.22B$6.86B$3.73B
Q3 2021Sep 30, 2021$12.88B$6.64B$3.81B
Q2 2021Jun 30, 2021$12.60B$6.98B$3.73B
Q1 2021Mar 31, 2021$12.20B$6.58B$3.54B
Q4 2020Dec 31, 2020$12.27B$6.59B$3.62B
Q3 2020Sep 30, 2020$11.42B$6.15B$3.51B
Q2 2020Jun 30, 2020$10.75B$4.29B$3.30B
Q1 2020Mar 31, 2020$11.13B$5.93B$3.63B
Q4 2019Dec 31, 2019$10.55B$6.63B$3.57B
Q3 2019Sep 30, 2019$10.88B$6.38B$3.47B
Q2 2019Jun 30, 2019$10.53B$6.49B$3.54B
Q1 2019Mar 31, 2019$10.24B$6.46B$3.32B
Q4 2018Dec 31, 2018$10.19B$6.67B$3.54B
Q3 2018Sep 30, 2018$10.35B$6.59B$3.42B
Q2 2018Jun 30, 2018$10.35B$6.97B$3.50B
Q1 2018Mar 31, 2018$9.84B$6.77B$3.40B
Q4 2017Dec 31, 2017$9.68B$6.97B$3.54B
Q3 2017Sep 30, 2017$9.70B$6.60B$3.36B
Q2 2017Jun 30, 2017$8.63B$6.73B$3.48B
Q1 2017Mar 31, 2017$8.24B$6.29B$3.23B

Related KPIs